Document Type
Article
Department
Medical College Pakistan; Emergency Medicine; Haematology/Oncology; Pathology and Laboratory Medicine
Abstract
In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.
Publication (Name of Journal)
Leukemia Research Reports
Recommended Citation
Devi, K.,
Shaikh, M.,
Ali, N.,
Adil, S.,
Khan, M.,
Soomar, S. M.
(2021). Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. Leukemia Research Reports, 16, 100284.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/75
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Comments
Issue, and pagination are not provided by the author/publisher